Experiments demonstrated the potential of VDR agonists to set the CAFs back to a less pro-tumoral phenotype [129,130], highlighting the capability of calcitriol to exert a part of its anti-tumor activity, independent of the VDR status in tumor cells. This evidence concerns the gene VDR and neoplasm.